FDA and EMA accept Regeneron's myasthenia gravis therapy filings

Traders Union
All News
Companies
Regeneron Pharmaceuticals gains 0.41% today

Highlights

REGN remains under sustained downward pressure, trading below key short-, medium-, and long-term technical averages.
Bearish momentum dominates as multiple indicators simultaneously flag a strong sell bias and lack evidence of near-term reversal.
Price is expected to consolidate between $607.50 and $612.00 this week, with further downside risk if support breaks.

Downward bias as major averages converge with resistance boundaries

REGN is trading at $610.03, which is below the MA-20 ($618.41), MA-50 ($680.06), and MA-200 ($697.06). This configuration indicates persistent downward pressure across short-, medium-, and long-term timeframes. The Ichimoku Kijun sits at $661.06, which acts as immediate resistance. Near-term support is seen at the MA-20 ($618.41), with key support at the MA-50 ($680.06). Resistance levels are clustered at the MA-200 ($697.06) and the Ichimoku Kijun ($661.06).

Persisting bearish momentum amid weak trend signals and seller control

Momentum remains weak as the MACD on D1 delivers a strong sell signal and the ADX shows a sustained bearish trend. RSI on D1 sits at 37.92, confirming bearish momentum but not yet extreme oversold; Stoch RSI flags overbought conditions, while CCI indicates the asset remains under selling pressure. BBP reinforces this with a pronounced "oversold" reading, pointing to clear intraday dominance by sellers. The Awesome Oscillator does not currently support the trend. Over the past week, REGN has declined $1.41 (0.23%) from a previous weekly close of $611.44 to the current $610.03, with prices moving in the middle of the weekly range and weekly volatility at 3.60%. The weekly tone signals consolidation after testing both the high ($620.00) and low ($598.45) of the range.

Downside risk favored unless key resistance cluster is reclaimed

Looking ahead, the expected price range for REGN over the coming week is $607.50 to $612.00, using typical volatility parameters and consistent with movements seen between the 52-week low ($506.80) and high ($820.37). Technical readings from W1 (SMA/EMA, RSI, ADX, MACD) are uniformly bearish, suggesting a very high probability (more than 80%) of further downside, with an increase being much less likely. The baseline scenario envisions prices remaining confined to a narrow, sideways band. A bullish breakout would require a move above the Ichimoku Kijun and MA-20 resistance cluster. A bearish scenario unfolds if REGN breaks below immediate support near $607.50, exposing the asset to further downside toward longer-term lows.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier, analysts noted that Regeneron Pharmaceuticals was experiencing persistent technical weakness and institutional repositioning, suggesting caution amid downward pressure. In light of the latest developments described above, investors should monitor for signs of stabilization or a potential shift in momentum, as any decisive move could set the stage for the next directional trend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.